A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Phase 1 Terminated 14 enrolled ALX Oncology Inc.

NaSingle-groupOpen-labelTreatment

Summary

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).

Timeline

Start: 2021-05-05
Primary completion: 2023-05-05
Completion: 2023-08-16

Publications

Marks JA, Wang X, Fenu EM, Bagg A, Lai C. TP53 in AML and MDS: The new (old) kid on the block. Blood Rev. 2023 Jul;60:101055. doi: 10.1016/j.blre.2023.101055. Epub 2023 Feb 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evorpacept	Protein / enzyme biologic	—	—
Background	Azacitidine	Other / unclassified	—	—
Background	Venetoclax	Small molecule	—	—

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

Summary

Timeline

Publications

Drugs

Indications